ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients | Zendy

Johan Maertens | Zendy; Simone Cesaro | Zendy; Georg Maschmeyer | Zendy; Hermann Einsele | Zendy; J. Peter Donnelly | Zendy; Alexandre Alanio | Zendy; Philippe M. Hauser | Zendy; Katrien Lagrou | Zendy; Willem J. G. Melchers | Zendy; Jannik HelwegLarsen | Zendy; Olga Matos | Zendy; Stéphane Bretagne | Zendy; Catherine Cordonnier | Zendy

Open Access

ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

Author(s) -

Johan Maertens,

Simone Cesaro,

Georg Maschmeyer,

Hermann Einsele,

J. Peter Donnelly,

Alexandre Alanio,

Philippe M. Hauser,

Katrien Lagrou,

Willem J. G. Melchers,

Jannik HelwegLarsen,

Olga Matos,

Stéphane Bretagne,

Catherine Cordonnier

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw157

Subject(s) - medicine , pneumocystis jirovecii , pentamidine , rituximab , regimen , fludarabine , alemtuzumab , trimethoprim , dapsone , pneumocystis pneumonia , pneumonia , intensive care medicine , pediatrics , immunology , cyclophosphamide , transplantation , chemotherapy , antibiotics , lymphoma , microbiology and biotechnology , biology

The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Recommendations were based on the grading system of the IDSA. Trimethoprim/sulfamethoxazole given 2-3 times weekly is the drug of choice for the primary prophylaxis of PCP in adults ( A-II: ) and children ( A-I: ) and should be given during the entire period at risk. Recent data indicate that children may benefit equally from a once-weekly regimen ( B-II: ). All other drugs, including pentamidine, atovaquone and dapsone, are considered second-line alternatives when trimethoprim/sulfamethoxazole is poorly tolerated or contraindicated. The main indications of PCP prophylaxis are ALL, allogeneic HSCT, treatment with alemtuzumab, fludarabine/cyclophosphamide/rituximab combinations, >4 weeks of treatment with corticosteroids and well-defined primary immune deficiencies in children. Additional indications are proposed depending on the treatment regimen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research